Difelikefalin to be reviewed for use in the EU for pruritus associated with chronic kidney disease in haemodialysis patients

The filing for this peripheral κ-opioid receptor specific agonist is supported by positive clinical data from the two pivotal phase-III trials KALM-1 and KALM-2, as well as supportive data from an additional 32 clinical studies. Regulatory decision is expected Q2 2022.

Source:

Biospace Inc.